The clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated (Cas) system induces an adaptive immune response against invading phages and plasmids in bacteria and archaea (Wiedenheft et al. 2012 ). Cas9, a protein derived from Streptococcus pyogenes, is complexed with CRISPR RNA (crRNA), whose sequence is originated from phages and plasmids, and trans-activating crRNA (tracrRNA) to form an active DNAcleaving endonuclease whose specificity is determined by WatsonCrick base pairing between crRNA and the target DNA of 20 bp in length and by the NGG-trinucleotide protospacer adjacent motif (PAM) recognized by Cas9. A single-guide RNA (sgRNA) generated by fusing crRNA and tracrRNA is also functional and can reprogram Cas9 protein to cleave a specific DNA sequence ( Fig. 1A ; Jinek et al. 2012) . Thus, Cas9 is an RNA-guided endonuclease (RGEN) that protects microbial cells from invading phages and plasmids by digesting their DNA site-specifically, reminiscent of restriction endonuclease-mediated protection of host cells from foreign genetic elements. Unlike restriction endonucleases, however, the Cas9 specificity is readily reprogrammed by replacing crRNA, making these nucleases ideal tools for genome engineering in higher eukaryotic cells and organisms.
Recent studies have shown that Cas9-derived RGEN is, indeed, a new member in the growing family of genome editing nucleases (Bassett et al. 2013; Chang et al. 2013; Cho et al. 2013a; Cong et al. 2013; DiCarlo et al. 2013; Friedland et al. 2013; Hwang et al. 2013b; Jiang et al. 2013; Jinek et al. 2013; Mali et al. 2013; Shen et al. 2013; Wang et al. 2013; Xiao et al. 2013) , which include zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). These programmable nucleases induce site-specific DNA double-strand breaks (DSBs) in cells, whose repair via high-fidelity homologous recombination or error-prone nonhomologous end-joining (NHEJ) gives rise to targeted mutations (Bibikova et al. 2003; Kim et al. 2009; Kim et al. 2010; Miller et al. 2010) or chromosomal rearrangements (Brunet et al. 2009; Lee et al. 2009 Lee et al. , 2011 . For example, Shen et al. (2013) demonstrated that RGENs induced mutations in a reporter gene in transgenic mouse lines. Wang et al. (2013) used RGENs to induce multiple mutations in a single step in mice. Although these initial pioneering results are encouraging, it is unknown whether and how efficiently the RGEN-induced mutations detected in embryos or pups can be transmitted to the next generation, a process required for the establishment of gene-knockout (KO) animals. Here, we show that the injection of Cas9 protein complexed with guide RNA or Cas9 mRNA plus guide RNA into one-cell embryos gives rise to germline-transmittable mutations in vertebrate animals.
Results

RGEN design and production
To examine the gene knockout potential of RGENs in pronuclear (PN)-stage mouse embryos, we selected the forkhead box N1 (Foxn1) gene, which is important for thymus development and keratinocyte differentiation (Nehls et al. 1996) , and the protein kinase, DNA activated, catalytic polypeptide (Prkdc) gene, which encodes an enzyme critical for DNA DSB repair and recombination (Taccioli et al. 1998) . We designed several sgRNAs specific to exon 2 in the Foxn1 gene (Supplemental Fig. 1A ) and exon 2 in the Prkdc gene (Fig. 1B ). First, we tested the in vitro DNA-cleavage activities of RGENs com-posed of synthetic sgRNA and recombinant Cas9 protein expressed in and purified from Escherichia coli ( Fig. 1C; Supplemental Fig. 1B) . The Foxn1-and Prkdc-specific sgRNAs that manifested the highest activities were chosen for the subsequent in vivo experiments (#3 and #2, respectively) ( Fig. 1C; Supplemental Fig. 1B ).
Generation of founder mice with RGEN-induced mutations
To evaluate the genome-editing activity of the Foxn1-RGEN, we injected Cas9 mRNA (10 ng/mL solution) with various doses of the sgRNA into the cytoplasm of PN-stage mouse embryos and conducted T7 endonuclease I (T7E1) assays ) using genomic DNAs obtained from in vitro-cultivated embryos (Supplemental Fig. 2A ). Mutant fractions (the number of mutant embryos/the number of total embryos) were dose dependent, ranging from 31% (1 ng/mL sgRNA) to 87% (100 ng/mL) (Supplemental Fig.  2B ). Sequence analysis confirmed mutations in the Foxn1 gene; most mutations were small deletions (Supplemental Fig. 2C ), reminiscent of those induced by ZFNs and TALENs . Notably, ;90% of the RGEN-injected embryos developed to blastocysts and then hatched from the zona pellucida, suggesting that RGENs were not cytotoxic under our experimental conditions (Supplemental Fig. 2B) .
Encouraged by the high mutant frequencies and low cytotoxicity induced by RGENs, we produced live animals by transferring the mouse embryos into the oviducts of pseudo-pregnant foster mothers (Supplemental Fig. 3A-C ; Table 1 ). Notably, the birth rates were very high, ranging from 58% to 73%, and were not affected by the increasing doses of Foxn1-sgRNA (Table 1) . Out of 147 newborns, we obtained 99 mutant founder mice (Table 1) . Consistent with the results observed in cultivated embryos (Supplemental Fig. 2B ), mutant fractions were proportional to the doses of Foxn1-sgRNA, and reached up to 93% (100 ng/mL Foxn1-sgRNA) ( Table 1 ). To generate Prkdc-targeted mice and to test whether higher doses of RGENs are tolerated in embryos, we applied a fivefold higher concentration of Cas9 mRNA (50 ng/mL) with increasing doses of Prkdc-sgRNA (50, 100, and 250 ng/mL). Again, the birth rates were very high, ranging from 37% to 60%, enough to produce a sufficient number of newborns for the analysis ( Fig. 2 ; Table 1 ). The mutant fraction was 57% (21 mutant founders among 37 newborns) at the maximum dose of Prkdc-sgRNA (Table 1 ). These birth rates obtained with RGENs were approximately twofold to 10-fold higher than those obtained with TALENs targeting two unrelated genes, which were reported in our previous study (Sung et al. 2013 ), on par with those of transgenic mouse production (Nagy et al. 2003 ). These results demonstrate that RGENs are potent gene-disrupting reagents with minimal toxicity.
Fluorescent PCR (fPCR) ( (77) 94 (49) 91 (48) 39 (43) Percentages were calculated using the number in each column as the numerator and the number in the column to its left as the denominator. a After eliminating the numbers of pups that were cannibalized at birth, the percentages were calculated using the numbers of transferred embryos as the denominator. b Determined by T7E1 assays.
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Cold Spring Harbor Laboratory Press on July 31, 2017 -Published by genome.cshlp.org Downloaded from cleavage of one-cell embryos (Supplemental Table 1 ). Notably, nine mice (27%) harbored bi-allelic mutations with no wild-type allele. Similar mosaic patterns were also observed in Prkdc mutant mice (20/39 founders, 51%) (Supplemental Table 2 ). In addition, identical mutant alleles were often observed for both Foxn1 and Prkdc genes (Supplemental Tables 3, 4 ). For example, we identified three founder mice with homozygous mutations in the Foxn1 gene (Supplemental Table 1 ).
Gene disruption by Cas9 protein-sgRNA complex in mice and zebrafish Alternatively, we directly injected the RGEN in the form of recombinant Cas9 protein harboring a nuclear localization signal (NLS) (0.3-30 ng/mL) complexed with Foxn1-specific sgRNA (0.14-14 ng/mL) into the cytoplasm or pronucleus of one-cell mouse embryos and analyzed mutations in the Foxn1 gene using in vitro cultivated embryos (Supplemental Fig. 4 ). These injection doses and methods minimally affected the survival and development of mouse embryos in vitro: >70% of RGEN-injected embryos normally hatched from the zona pellucida in both experiments. Again, mutant fractions obtained with Cas9 protein injection were dose dependent, and reached up to 88% at the highest dose via pronucleus injection and to 71% via intracytoplasmic injection (Supplemental Fig. 4A,B) . Similar to the mutation patterns induced by Cas9 mRNA plus sgRNA (Supplemental Fig. 3C ), those induced by the Cas9 protein-sgRNA complex were mostly small deletions (Supplemental Fig.  4C) . These results clearly demonstrate that the proteinaceous RGEN has high genedisrupting activity in mouse embryos.
We also tested whether proteinaceous RGENs could induce mutations in zebrafish embryos. We designed RGENs that target the exogenous GFP reporter gene or an endogenous gene, microphthalmiaassociated transcription factor a (mitfa), which encodes a master regulator of melanocyte development in vertebrates ( Fig. 3A,B ; Lister et al. 1999; Park et al. 2000) . Injection of up to 8 ng of Cas9 protein complexed with mitfa-specific sgRNA did not perturb normal development in >80% of the embryos (Supplemental Fig. 5 ). When embryos were injected with Cas9 protein plus mitfa-or GFP-specific sgRNA, mutations were detected at target sites in a dose-dependent manner (Fig. 3A,B) . A time-course experiment revealed that the Cas9 protein:sgRNA complex triggered mutations as early as at 4 h post-injection stage, 2 h faster than did Cas9 mRNA plus sgRNA (Fig. 3C) . A subset of zebrafish embryos coinjected with Cas9 protein:mitfa-specific sgRNA manifested defects in melanocyte development (Supplemental Fig. 7 ), demonstrating that some of their somatic tissues were nullizygous for the mitfa gene. These results indicate that RGENs injected as Cas9 protein:sgRNA complexes can exert sufficient gene-disrupting activities to induce null mutations at both endogenous and exogenous genomic loci at an early developmental stage in zebrafish embryos.
Analysis of off-target effects of RGENs
We examined whether the RGENs generated off-target mutations in the mouse genome. We searched for possible off-target sites that included 1-to 3-bp mismatches with the sgRNA target sequence. A total of four and 63 such sites were found for the Foxn1 and Prkdc target sequences, respectively, in the entire mouse genome. T7E1 assays were conducted using genomic DNA samples from the founder mice obtained with the highest doses of Foxn1-and Prkdc-sgRNAs. These founder mice were bi-allelic or mosaic mutants (Supplemental Tables 1, 2 ). Even though these mutant founders were produced using high levels of RGENs in one-cell embryos, no off-target activities were detected in any of the four genomic loci that were highly homologous with the target sequence of Foxn1-RGEN or any of the six such sites of the Prkdc-RGEN ( Fig. 4; Supplemental Fig. 8 ). Of note is the absence of T7E1-detectable mutations at sites with a single-base mismatch in the putative 11-base seed region near the GG-dinucleotide PAM (e.g., Prkdc Off5 and Foxn1 Off3 in Fig. 4 and Supplemental Fig. 8) or with a perfect match in the seed region and 2-or 3-base mismatches upstream of the seed region (Prkdc Off3, Off4, and Off6 in Fig. 4) . 
Phenotype analysis and germline transmission of Prkdc-mutant mice Targeted deficiency of the Prkdc gene in mice results in severe combined immunodeficiency (Taccioli et al. 1998 ). For the functional validation of RGEN-induced mutations of the Prkdc gene in mice, we evaluated the immunological phenotypes of F 0 mutant founders using peripheral blood mononuclear cells (PBMCs). The mosaic founder #1 carried a wild-type allele (Supplemental Table 2 ) and showed comparable B-and T-cell populations to those of the wild-type BALB/c mouse (Supplemental Fig. 9 ). On the other hand, the mutant founder #47 possessed bi-allelic null mutations in the Prkdc gene, and these immune cell populations were significantly lowered in the PBMC (Supplemental Fig. 9 ), indicating the functional loss of the Prkdc gene.
To test the germline transmission of the mutant alleles of the Prkdc gene, we crossed the male founder #25 (D269/D61/WT) with female founder #33 (D4/+2/WT) (Supplemental Table 2 ) and monitored the genotypes of the F 1 offspring (Fig. 5A) . As expected, all the progenies were wild type or inherited one or two mutant alleles from their parents (Fig. 5A) . We also confirmed the germline transmission of Foxn1 mutant alleles from the Foxn1 founder #108 and observed the segregation of the mutant alleles in the progenies (Supplemental Fig. 10 ).
As expected, the bi-allelic Prkdc mutant progeny showed a null phenotype (Fig. 5A) . Compared with the wild-type BALB/c mouse and the progeny #1 carrying a wild-type allele, the bi-allelic mutant progeny #7 exhibited defects in B-and T-cell populations (Fig. 5B,C) . Thus, lymphocytes isolated from PBMC and from the primary and secondary lymphoid organs including thymus, spleen, and lymph node were defective in B-and T-cell populations (Fig. 5B) . Compared with severe combined immunodeficiency (scid) mice, the mutant mouse exhibited phenotypic leakiness. For example, the F 1 progeny had 1.79% CD4 + and 1.07% CD3 + T cells, whereas the T-cell populations examined were <1% in the scid mouse (Fig. 5B ). These small differences between scid and the bi-allelic mutant mice might reflect the differences in their genetic backgrounds, ages, or genotypes. Overall, these results clearly proved the functional loss of the Prkdc gene by RGEN-mediated gene knockout in mice.
Discussion
Our study provides strong evidence that RGENs hold great promise for generations of knockout mice and zebrafish. Although there were recent reports describing the (EA) generations of mutant mice using RGENs (Shen et al. 2013; Wang et al. 2013) , germline transmission of the mutations induced by RGENs has not been confirmed. We showed that RGEN-induced mutant alleles were stably transmitted to F 1 progenies in vertebrate animals and confirmed the mutant phenotypes using both founder mice and F 1 mutant progenies. In addition, we also showed that recombinant Cas9 protein complexed with sgRNA induced mutations in both mice and zebrafish, which potentially broadens the range of the RGEN application for in vivo mutagenesis. Nuclease proteins might have different kinetics and half-lives in cells, when delivered directly, as compared with being produced by gene-or mRNA-mediated expression, potentially alleviating off-target effects (Izmiryan et al. 2011; Gaj et al. 2012) . Unlike recombinant ZFNs and TALENs whose purification is cumbersome, timeconsuming, and laborious, new proteinaceous RGENs are prepared simply by mixing Cas9 protein with different sgRNAs or dualRNAs. These features strongly support the notion that RGENs are convenient and efficient tools for gene knockout in model organisms.
The specificity of RGENs is of concern. Because RGENs are derived from prokaryotes, whose genomes are much smaller than those of higher eukaryotes, RGENs may have off-target effects in animals, plants, and cultured human cells such as stem cells. Furthermore, unlike ZFNs and TALENs, which function as dimers that enhance specificity, RGENs act as monomers. Recent in vitro studies conducted using cell lines have provided the evidence of off-target mutations induced by RGENs (Cong et al. 2013; Fu et al. 2013; Hsu et al. 2013; Pattanayak et al. 2013 ). Fortunately, however, our analyses of off-target effects suggest that RGENs might not be associated with highly frequent off-target mutations in vivo or in clones. Unlike in vitro experiments using cell populations, our in vivo experiments analyzed individual offspring or clones. Off-target mutations present in cell populations can be diluted out in individual clones. In addition, some of the rare offtarget mutations in the founders can be removed during mating. Although it is possible that the RGENs induced off-target mutations at sites that are not analyzed in this study, our results suggest that RGENs are specific enough to allow targeted mutagenesis in the mouse. A careful choice of target sites that lack highly homologous sequences elsewhere in the genome should be useful for avoiding or minimizing unwanted off-target mutations as much as possible Kim et al. 2013a) .
On the basis of these results, we propose that RGEN-mediated in vivo mutagenesis will greatly expedite the creation of genetically engineered model organisms and thereby accelerate functional genomic research. Recently, three groups (Fujii et al. 2013; Hwang et al. 2013a; Li et al. 2013 ) have independently reported germline transmission of RGEN-induced mutations in zebrafish, mice, and rats, demonstrating broad utility of RNA-guided genome editing in vertebrate model organisms. We also note that we have used proteinaceous RGENs to disrupt genes in Caenorhabditis elegans (Cho et al. 2013b ).
Methods
RGEN components
Cas9 mRNA and sgRNAs were synthesized in vitro from linear DNA templates using the mMESSAGE mMACHINE T7 Ultra kit (Ambion) and MEGAshortscript T7 kit (Ambion), respectively, according to the manufacturer's instructions, and were diluted with appropriate amounts of diethyl pyrocarbonate (DEPC, SigmaAldrich)-treated injection buffer (0.25 mM EDTA, 10 mM Tris at pH 7.4). Templates for sgRNA synthesis were generated using the oligonucleotides listed in Supplemental Table 5 as described previously (Cho et al. 2013a ). Recombinant Cas9 protein (Cho et al. 2013a ) was obtained from ToolGen, Inc.
In vitro cleavage reactions
A restriction enzyme-treated linearized plasmid (5 nM) was incubated for 60 min at 37°C with Cas9 protein (20 nM), and sgRNA (40 nM) in 13 NEB 3 buffer. Reactions were stopped with 63 stop solution containing 30% glycerol, 1.2% SDS, and 100 mM EDTA. Products were resolved with 1% agarose gel electrophoresis and were visualized with ethidium bromide (EtBr) staining.
Microinjection of RGENs into mouse embryos
All animal experiments were performed in accordance with the Korean Food and Drug Administration (KFDA) guidelines. Protocols were reviewed and approved by the Institutional Animal Care and Use Committees (IACUC) of the Laboratory Animal Research Center at Yonsei University (Permit Number: 2013-0099) . All mice were maintained in the specific pathogen-free (SPF) facility of the Yonsei Laboratory Animal Research Center.
FVB/NTac (Taconic) and ICR (DBL, Korea) mouse strains were used as embryo donors and foster mothers, respectively. Female FVB/NTac mice (7-8 wk old) were superovulated by intraperitoneal injections of 5 IU of pregnant mare serum gonadotropin (PMSG, Sigma-Aldrich) and 5 IU of human chorionic gonadotropin (hCG, Sigma-Aldrich) at a 48-h interval. The superovulated female mice were mated to FVB/NTac stud males, and fertilized embryos were collected from oviducts.
Cas9 mRNA and sgRNAs in M2 medium (Sigma-Aldrich) were injected into the cytoplasm of fertilized eggs with well-recognized pronuclei using a Piezo-driven micromanipulator (Prime Tech). The recombinant Cas9 protein:Foxn1-sgRNA complex was diluted with DEPC-treated injection buffer (0.25 mM EDTA, 10 mM Tris at pH 7.4) and injected into male pronuclei using a TransferMan NK2 micromanipulator and a FemtoJet microinjector (Eppendorf). The manipulated embryos were transferred into the oviducts of pseudopregnant foster mothers to produce live animals or were cultivated in vitro for further analyses. 
Fluorescent PCR
One hundred nanograms of genomic DNA was amplified by PCR using 59-6-carboxyfluorescein (6-FAM)-labeled primers (F2) (Supplemental Table 6 ). PCR products were resolved using an ABI 3730xl DNA analyzer, and fPCR results were analyzed using a Peak scanner v1.0.
Genotyping, sequence analyses, and phenotyping of mutant mice
To screen F 0 mice and in vitro-cultivated mouse embryos with RGEN-induced mutations, T7E1 assays were performed as previously described using genomic DNA samples from tail biopsies and lysates of whole embryos (Cho et al. 2013a) . Briefly, the genomic region encompassing the RGEN target site was PCR-amplified, melted, and reannealed to form heteroduplex DNA, which was treated with T7 endonuclease 1 (New England Biolabs) and then analyzed by agarose gel electrophoresis. For the newborn mice that were negative in the T7E1 assays, additional T7E1 assays were conducted by mixing equal amounts of wild-type PCR products. Potential off-target sites were identified by searching with Bowtie 0.12.9 (Langmead et al. 2009 ) and were also similarly monitored by T7E1 assays. The primer pairs used in the T7E1 assays were represented in Supplemental Tables 6 and 7. Mutant founders identified by the T7E1 assay were further analyzed by fPCR. For routine PCR genotyping of F 1 progenies, the following primer pairs were used for both wild-type and mutant alleles: 59-CTACTCCCTCCGCAGTCTGA-39 and 59-CCAGGCCT AGGTTCCAGGTA-39 for the Foxn1 gene, 59-CCCCAGCATTGCAG ATTTCC-39 and 59-AGGGCTTCTTCTCTACAATCACG-39 for the Prkdc gene.
Characterization of immune cells by flow cytometry
BALB/c mice were purchased from DBL (Korea), and C.B.-17 scid mice (C.B-Igh-1 b /IcrTac-Prkdc scid ) were imported from Taconic. Lymphocytes were prepared and processed as previously described (Park et al. 2000) . PerCP-, APC-, V605-, V421-, PE-Cy7-, and PerCPCy5.5-conjugated antibodies specifically detecting CD3e (145-2C11), CD19 (1D3), CD4 (RM4-5), and CD8 (53-6.7), respectively, were purchased from BD Biosciences or Biolegend. Flow cytometry was performed with FACS Calibur and FACS CantoII (BD Biosciences), and the data were analyzed using the FlowJo software (Tree Star). Table 2 ). Using lymphocytes isolated from peripheral blood (PBMC), lymph node (LN), spleen, and thymus, frequencies of CD4 + and CD8 + T cells (B) and those of CD3 + T cells and CD19 + B cells (C ) were determined. The abnormal frequencies of immune cells are denoted in red. BALB/c and scid mice, positive and negative controls for B and T lymphocytes, respectively.
Procedures of RGEN-mediated mutagenesis in zebrafish embryos
Wild-type and Tg[huC:GFP] transgenic zebrafish were maintained at 28.5°C on a 14-h light/10-h dark cycle. Embryonic stages were determined by the post-fertilization hour and microscopic observation. Animal work was approved by the internal animal ethics committee at Chungnam National University (CNU-00191).
One-cell-stage zebrafish embryos were injected with the indicated doses of Cas9 protein solution (7 mg/mL) containing crRNA (1 mg/mL), tracrRNA (2 mg/mL), or sgRNA (2.5 mg/mL). The injected embryos were incubated at 28.5°C for the indicated points, and their phenotypes and genotypes were examined. Genomic DNA was extracted from developing zebrafish embryos using a genomic DNA purification system (Promega) following the manufacturer's instructions. Targeted genomic loci were amplified from five pooled embryos using primers designed to flank the Cas9 complex target site and cloned into the pGEM T-easy vector (Promega). The cloned segments were then sequenced (Genotech). T7E1 assays were performed as described above.
